Skip to main content

Radiopharm Theranostics talks clinical development and Nasdaq listing

--News Direct--

Radiopharm Theranostics Ltd (ASX:RAD) CEO and managing director Riccardo Canevari tells Proactive the company has begun the initiation process for entry into the Nasdaq stock exchange under the ticker RADX, gaining a second listing in the US capital market. RAD’s recently announced that it has received US FDA Investigational New Drug Application (IND) approval for its αVβ6 Integrin (RAD301) technology. With this approval the company can start a Phase 1 imaging trial in ambulatory patients with pancreatic cancer.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/radiopharm-theranostics-talks-clinical-development-and-nasdaq-listing-330445820

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.